Ongoing Investigation of iRhythm Technologies
New York based Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti, Jr., is actively investigating iRhythm Technologies, Inc. (NASDAQ: IRTC). The firm is probing potential breaches of fiduciary duty by the company’s directors and officers. The focus is on their responsibilities to shareholders in light of recent legal developments.
Insights into Recent Regulatory Issues
iRhythm Technologies faced a significant setback when the FDA issued a Warning Letter concerning serious regulatory violations involving their Zio AT System. This warning highlighted critical deficiencies related to device reporting requirements, which may pose risks to patients. Reasons for concern include undisclosed limitations regarding the transmission of arrhythmia events and other health-related issues.
Legal Consequences Following FDA Complaints
Following the FDA’s Warning Letter, a securities class action lawsuit was filed against iRhythm and its executives. The lawsuit claims the company failed to disclose vital information that could affect investor decisions, breaching federal securities laws. The court recently allowed the case to advance, denying the company’s attempt to dismiss the claims.
Investigating Potential Violations
Kahn Swick & Foti’s investigation aims to determine if iRhythm’s leadership acted in ways that were not in line with their legal obligations to shareholders. This inquiry is crucial as it aims to ensure that all stakeholders are informed and adequately protected against potential misconduct.
How You Can Contribute
If you possess information pertinent to the investigation or have held shares in iRhythm for an extended period, KSF invites you to share your insights. The firm offers a no-obligation consultation to discuss your legal rights. You can reach out by calling 1-833-938-0905 or by contacting Managing Partner Lewis Kahn via email.
About Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC is recognized as a leading boutique securities litigation firm in the U.S. Their commitment to defending the rights of investors has earned them a robust reputation, particularly following a ranking as one of the top firms for total settlement value. The firm has successful recovery experiences for both institutional and private investors, driven by their dedication to combatting corporate fraud.
KSF's Broader Mission
By providing resources and expertise, KSF stands up for investors impacted by poor corporate governance. With offices across several states and a representative office in Luxembourg, their reach and impact are notable, allowing them to serve diverse clients effectively.
Frequently Asked Questions
What is the current status of the investigation into iRhythm?
Kahn Swick & Foti is actively investigating potential breaches of fiduciary duty by iRhythm's officers and directors.
Why was the FDA Warning Letter significant?
The FDA Warning Letter outlined serious compliance issues regarding iRhythm's Zio AT System, raising concerns about patient safety.
What legal actions has iRhythm Technologies faced?
The company is currently facing a securities class action lawsuit alleging failure to disclose crucial information to shareholders.
How can I contribute to KSF's investigation?
If you have relevant information, you are encouraged to contact KSF toll-free or reach out to Managing Partner Lewis Kahn via email.
What is the reputation of Kahn Swick & Foti?
KSF is recognized as one of the leading securities litigation firms in the U.S., noted for their efforts in securing settlements for investors.
